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a b s t r a c t 
Respiratory syncytial virus (RSV)-induced bronchiolitis in infants, although inﬂammatory in nature, is
not responsive to glucocorticoids. We have recently shown that RSV-infected lung epithelial cells have
impaired glucocorticoid receptor (GR)-mediated transactivation. In this study, we show that the N-
terminal region of GR is required for RSV repression of GR transactivation and that RSV infection of lung
epithelial cells reduces ligand-dependent GR phosphorylation at serine 211 and serine 226. However,
we also show that these changes in GR phosphorylation do not account for the RSV repression of GR
transactivation suggesting other regions of the GR N-terminus must also be involved. 
C © 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical






























 1. Introduction 
Respiratory syncytial virus (RSV) is the major cause of severe lower
respiratory tract infections in children, resulting in 132,000–172,000
infant hospitalizations / year in the USA alone [ 1 ]. Treatment of severe
RSV symptoms in children is estimated to cost $600 billion per year
in the USA [ 2 ]. In addition to children, immunocompromised adults
and the elderly are also at risk from severe RSV disease [ 3 , 4 ]. 
RSV is a negative-sense single-stranded RNA pneumovirus of the
Paramyxoviridae family that causes bronchiolitis, an inﬂammatory
disease of the bronchioles. Glucocorticoids, one of the most pow-
erful anti-inﬂammatory agents available, have no beneﬁcial effect for
infants with RSV-induced bronchiolitis [ 5 –8 ]. In addition, glucocorti-
coids show impaired suppression of RSV-induced cytokines in in vitro
assays [ 9 –11 ]. These data, suggest that RSV may have a deleterious
effect on glucocorticoid signaling. In fact, we have recently shown
that RSV infection represses glucocorticoid receptor (GR)-mediated
transactivation [ 11 ].  
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http://dx.doi.org/10.1016/j.fob.2013.07.005 Glucocorticoids play an important role in regulating many systems
including the immune system. They function through GR, a cytosolic
receptor. Upon ligand binding, GR dissociates from a protein com-
plex, dimerizes and translocates to the nucleus where it binds to
speciﬁc DNA sequences, glucocorticoid response elements (GREs), to
activate gene transcription. GR consists of three functional domains
– N-terminal transactivation domain, central DNA binding domain
(DBD) and the C-terminal ligand binding domain (LBD). The ability to
activate gene transcription is dependent on two activation domains,
AF1 and AF2, located in the N-terminus and C-terminal LBD, respec-
tively. In addition, transcriptional activity can also be modulated by
phosphorylation [ 12 , 13 ]. 
We have previously shown that RSV infection impairs GR-
mediated transactivation by interfering with GR binding to the GREs
in the promoters of responsive genes [ 11 ]. In this study we show
that RSV infection also results in reduced GR phosphorylation, but
changes in phosphorylation alone cannot account for the repression
of GR-mediated transactivation observed in RSV-infected lung ep-
ithelial cells. 
2. Materials and methods 
2.1. Materials 
Dexamethasone was purchased from Sigma–Aldrich (St. Louis,
MO) and was dissolved in 99.5% ethanol. Calyculin A was purchased
from Cell Signaling Technology, Inc. (Danvers, MA) and okadaic acid
from EMD Millipore (Billerica, MA). Both were dissolved in DMSO. an Biochemical Societies.  Open access under CC BY-NC-ND license.






















































 .2. Cell culture 
A549 cells, an alveolar cell carcinoma derived cell line which re- 
ains features of the type II alveolar epithelial cells, is routinely used 
s a model for RSV infection of epithelial cells [ 14 ]. A549 cells (Amer- 
can Type Culture Collection (ATCC), Manassas, VA) were grown in 
MEM / F12 (50 / 50) media with 10% fetal bovine serum (FBS) and 
os7 cells (ATCC), were grown in DMEM media with 10% FBS at 37 ◦C 
nd 5% CO 2 . 
.3. Virus preparation and infection 
Recombinant green ﬂuorescent protein (GFP)-expressing RSV 
rgRSV) was grown in HeLa cells, separated from debris by low speed 
entrifugation and further puriﬁed by pelleting in a high speed cen- 
rifuge [ 11 , 15 ]. Viral adsorption was performed as previously de- 
cribed [ 11 ]. Successful infection was conﬁrmed by the presence of 
FP viewed under a ﬂuorescent microscope. 
.4. Transient transfection 
Cos7 cells were plated in 24-well cell culture plates in DMEM con- 
aining 10% CSS at a concentration of 5 × 10 4 cells / well. The next day 
ells were transfected with 20 ng GR, 100 ng of the GR-responsive pro- 
oter, MMTVLuc or the GAL-4-responsive promoter, FRLuc promoter 
Agilent Technologies, Santa Clara, CA), 20 ng of the renilla internal 
ontrol, pRL TK (Promega Corp., Madison, WI) and 360 ng pSG5 using 
ransIT-LT1 (Mirus Bio, Madison, WI) according to the manufacturer’s 
nstructions. The following day the cells were inoculated with rgRSV 
multiplicity of infection (MOI) = 3). After 1 h the inoculum was re- 
laced with media containing vehicle or 100 nM dexamethasone. 
fter 5 or 24 h the cells were lysed and luciferase measured using 
he Dual Luciferase Assay (Promega Corp.) on a Packard LumiCount 
uminometer (PerkinElmer, Waltham, MA). 
.5. Western blotting 
Total cellular protein was isolated using M-PER in the presence 
f protease and phosphatase inhibitors (Thermo Fisher Scientiﬁc Inc., 
ittsburgh, PA) according to the manufacturer’s instructions. 10 μg 
rotein was subjected to SDS–PAGE on NuPAGE Novex 4–12% bis–
ris pre-cast gels (Life Technologies, Grand Island, NY). Proteins were 
ransferred to nitrocellulose membranes by semi-dry blotting and 
locked in 5% non-fat dry milk in Tris-buffered saline–0.05% Tween 
0 (TBST). They were incubated with primary antibody in 5% milk in 
BST overnight at 4 ◦C. Membranes were washed three times with 
BST and incubated with secondary antibody in TBST for 1 h at room 
emperature. Membranes were again washed with TBST and chemilu- 
inescence detected using SuperSignal West Pico Chemiluminscence 
ubstrate (Thermo Fisher Scientiﬁc Inc.) according to the manufac- 
urer’s instructions and exposed to autoradiographic ﬁlm or visual- 
zed using a Kodak Image Station 4000MM Pro (Carestream Health 
nc., Rochester, NY). Membranes were stripped for 15 min at room 
emperature in Restore Stripping buffer (Thermo Fisher Scientiﬁc Inc.) 
nd re-probed as needed. Blots were quantiﬁed using ImageJ software 
NIH). Primary antibodies used were against phospho-GR (Ser211) 
Cell Signaling Technology Inc.; 4161; 1:1000), phospho-GR (Ser226) 
Abcam, Cambridge, MA; ab53692; 1:500), GR (H-300) (Santa Cruz 
iotechnology, Santa Cruz, CA; sc-8992; 1:1000), RSV (EMD Millipore; 
B1128; 1:5000) and β-actin (Santa Cruz Biotechnology; sc-47778; 
:2000). The secondary antibodies used were goat anti-rabbit IgG- 
RP (Santa Cruz Biotechnology; sc-2004; 1:2000), bovine anti-goat 
gG-HRP (Santa Cruz Biotechnology; sc-2350; 1:2000) and goat anti- 
ouse IgG-HRP (Santa Cruz Biotechnology; sc-2005; 1:5000). 2.6. Real-time PCR 
Total RNA was extracted using TRIzol (Life technologies) accord- 
ing to the manufacturer’s instructions. 500 ng RNA was reverse tran- 
scribed using the High Capacity cDNA Reverse Transcription Kit with 
RNase inhibitor (Life Technologies) in a 20 μl reaction. cDNA was 
then diluted by addition of 100 μl DEPC-treated H 2 O. Real-time PCR 
was performed on 8 μl diluted cDNA in a 20 μl reaction containing 
1 × Power SYBR ® Green PCR Master Mix (Life technologies) and 
0.125 μM of each primer ([ 11 ] and Table 1 ) using the following pro- 
tocol on an ABI 7300 Real-Time PCR system. Plates were heated at 
50 ◦C from 2 min, denatured for 10 min at 95 ◦C and subjected to 
40 cycles of 95 ◦C for 15 s and 60 ◦C for 1 min. Cycle threshold (C T )
values of duplicate samples were analyzed using the comparative 
CT ( C T ) method (Life technologies). The fold induction (2 
−Ct ) 
by dexamethasone was obtained by normalizing to two endoge- 
nous genes, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) 
and CAP-1 (Cyclic AMP-accessory protein) [ 16 ], and expressed rela- 
tive to the amount in non-treated cells. Relative copy numbers (RCN) 
were calculated as 2 −Ct × 100 [ 16 ]. 
2.7. siRNA-mediated gene silencing 
50 nM protein phosphatase 5 (PP5), pan protein phosphatase 1 
(PP1), protein phosphatase 2A (PP2A-C α) siRNA and control siRNA- 
A (Santa Cruz Biotechnology; sc-44602, sc-43545, sc-43509 and sc- 
37007, respectively) was transfected into A549 cells using Dharma- 
FECT 2 (Thermo Fisher Scientiﬁc Inc.,) according to the manufac- 
turer’s instructions. 48 h post transfection the cells were inoculated 
with rgRSV (MOI = 3). After 1 h the inoculum was removed and cells 
treated with vehicle or 100 nM dexamethasone and the expression 
glucocorticoid-inducible leucine zipper (GILZ) determined by real- 
time PCR. The efﬁciency of siRNA silencing was determined by real- 
time PCR. 
2.8. Cloning of pCMV HA-hGR S211A S226A double mutant 
The double mutant pCMV HA-hGR S211A S226A was generated by 
insertion of the S226A mutation into the pCMV HA-hGR S211A plas- 
mid using the QuikChange II Site-Directed Mutagenesis kit (Agilent 
Technologies) according to manufacturer’s instructions. Successful 
mutagenesis was conﬁrmed by sequencing. 
2.9. Statistical analysis 
Transfection experiments were performed in triplicate and real- 
time experiments in duplicate. The average values of n indepen- 
dent experiments were analyzed for statistical signiﬁcance us- 
ing the two-tailed unpaired Student’s t -test using Prism 5 soft- 
ware (* depicts p = 0.05–0.01; ** depicts p = 0.01–0.001; *** depicts 
p < 0.001). 
3. Results 
3.1. N-terminal region of GR is required for RSV repression of 
GR-mediated transactivation 
To deﬁne which region of GR was needed for the RSV repression 
of GR-mediated transactivation, expression plasmids for wild type 
rat GR (rGR) and the N-terminal deletions – pSG5 / GR407C, that lacks 
the N-terminal 407 amino acids of GR, but retains the DBD and LBD 
regions [ 17 ], and GAL / GR525C, that lacks the N-terminal 525 amino 
acids of GR, but retains purely the LBD attached to the gal 4 DBD [ 18 ], 
were used. In the absence of transfected GR, dexamethasone did not 
induce the MMTVLuc promoter, conﬁrming that Cos7 cells contain 
very little, if any, of their own GR. Dexamethasone induced a 48-fold 
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Table 1 
Real-time PCR primers. 
Gene name 
Accession 
number Direction Primer sequence (5 ′ -3 ′ ) Reference 
CAP-1 NM 006367.3 F ATTCCCTGGATTGTGAAATAGTC [ 16 ] 
R ATTAAAGTCACCGCCTTCTGTAG 
GAPDH NM 002046.3 F ACTTTGGTATCGTGGAAGGACT [ 16 ] 
R GTAGAGGCAGGGATGATGTTCT 
GILZ NM 004089 F GCACAATTTCTCCATCTCCTTCTT [ 11 ] 
R TCAGCATGATTCTTCACCAGATCCA 
PPP5C NM 006247.3 F GCTGGACATCGAGAGCATGACCATT 
R ACGAGCGTGCTCAGCTTGGA 
PPP1CA NM 002708.3 F CCTGCTGGAAGTGCAGGG 
R GAAGGTCGTAGTACTGGCCG 
PPP2CA NM 002715.2 F GCCTCTGCGAGAAGGCTAAA 
R CCCATGCACATCTCCACAGA 
Fig. 1. GR N-terminal region is required for RSV-mediated repression of 
dexamethasone-induced promoter activity. Cos7 cells were transfected with full length 
rGR, pSG5 / GR407C, or GAL / GR525C; MMTVLuc or the FRLuc promoter; and a control 
renilla vector. They were RSV (MOI = 3)- (black) or mock-infected (white) and then 
treated with dexamethasone for 5 h. Fireﬂy luciferase was normalized to renilla and 
fold increase following dexamethasone treatment calculated. Means and SD are shown 























Fig. 2. A protein phosphatase inhibitor reverses RSV-induced repression of 
dexamethasone-induced GR phosphorylation. A549 cells were mock- (lanes 1–3) or 
RSV (MOI = 3)-infected (lanes 4–5) and then at 5 h.p.i. treated with vehicle (lane 1) 
or 100 nM dexamethasone (lanes 2–5) for 30 min in the presence (lanes 3 and 5) or 
absence of 10 nM calyculin A. Similarly, cells were mock- (lanes 6–8) or RSV (MOI = 
1)-infected (lanes 9–11) and then at 24 h.p.i. treated with vehicle (lanes 6 and 9) or 
100 nM dexamethasone (lanes 7–8 and 10–11) for 30 min in the presence (lanes 8 and 
11) or absence of 10 nM calyculin A. Whole cell lysates were prepared and 10 μg pro- 
tein subjected to SDS–PAGE and western blotting using antibodies against phospho-GR 
(Ser211), phospho-GR (Ser226), total GR, RSV and β-actin (A). Total GR was normalized 
to β-actin for cells infected at an MOI = 3 (B) and MOI = 1 (C). Phospho GR (Ser 211) 
was normalized to total GR for cells infected at an MOI = 3 (D) and MOI = 1 (E). Phospho 
GR (Ser 226) was normalized to total GR for cells infected at an MOI = 3 (F) and MOI = 

















 increase in the MMTVLuc promoter activity in mock-infected, wild
type rGR transfected cells. RSV infection signiﬁcantly reduced the
induction of the MMTVLuc promoter to 26-fold. Dexamethasone in-
duced a 5.6-fold increase in the MMTVLuc promoter activity in mock-
infected, pSG5 / GR407C transfected cells that was not repressed by
RSV infection. Finally, dexamethasone induced a 26-fold increase in
the FRLuc promoter in mock-infected, GAL / GR525C transfected cells
that was not repressed by RSV infection ( Fig. 1 ). 
3.2. Effect of RSV infection on GR phosphorylation 
Within the N-terminal region of GR are phosphorylation sites that
are associated with transcriptional activity [ 12 , 13 ]. Dexamethasone
induces GR phosphorylation at serine 211 which is suppressed by RSV
infection. This suppression of dexamethasone-induced GR phospho-
rylation at serine 211 is seen at 5 hours post infection (h.p.i.) in RSV
(MOI = 3)-infected A549 cells ( Fig. 2 A, lanes 2 and 4, Fig. 2 D) and at
24 h.p.i. in RSV (MOI = 1)-infected cells ( Fig. 2 A, lanes 7 and 10, Fig.
2 E). Similar results were seen for dexamethasone-induced phospho-
rylation of GR at serine 226 ( Fig. 2 A, lanes 2 and 4, 7 and 10, Fig. 2 F and
G). No change in total GR levels was observed ( Fig. 2 A–C) as reported
previously [ 11 ]. 
3.3. Role of protein phosphatases in RSV repression of GR function 
We ﬁrst tested if inhibition of protein phosphatases could reverse
RSV effects on GR phosphorylation. The protein phosphatase inhibitor
calyculin A increased dexamethasone-induced GR phosphorylation at
both the serine 211 and serine 226 sites such that there was now no
difference between the mock- and RSV-infected cells ( Fig. 2 D, E, and
G), except for serine 226 at an MOI of 3 ( Fig. 2 F). We next tested if inhibition of protein phosphatases could reverse
RSV suppression of GR function. Dexamethasone induction of the
glucocorticoid-inducible gene, GILZ was repressed 76% by RSV infec-
tion in the absence of protein phosphatase inhibitors. Pre-treatment
with okadaic acid reduced this slightly, but not signiﬁcantly, to 60%
( Fig. 3 A). Likewise, pre-treatment with calyculin A also reduced this
slightly, but not signiﬁcantly, to 59% ( Fig. 3 B). 
We next tested if knock-down of protein phosphatases was able to
reverse the effects of RSV infection on GR-mediated transactivation.
RSV infection signiﬁcantly reduced dexamethasone induction of GILZ
in the absence and presence of all siRNAs ( Fig. 4 A). The RSV-mediated
% repression of dexamethasone-induced GILZ was not altered by the
presence of PP5, PP1 and PP2A siRNA ( Fig. 4 B). siRNA knock-down
was conﬁrmed by real-time PCR ( Fig. 4 C–E). 
3.4. Effect of RSV infection on GR phospho mutants 
To fully determine if the changes in GR phosphorylation are re-
quired for RSV repression of GR-induced gene activation, we used
plasmids expressing single serine to alanine point mutations in one
of the three GR phosphorylation sites: serine 211, 226 and 203 [ 13 , 19 ].
As we have seen changes in both serine 211 and 226 phosphorylation
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Fig. 3. Protein phosphatase inhibitors do not reverse RSV repression of 
dexamethasone-induced GILZ. A549 cells were RSV (MOI = 3)- or mock-infected and 
treated with okadaic acid (A) or calyculin A (B) for 30 min followed by treatment with 
vehicle or 100 nM dexamethasone for 5 h. Dexamethasone-induced GILZ mRNA was 
determined by real-time PCR and normalized to GAPDH and CAP-1. % repression by 
RSV was calculated as a percentage of ((fold increase mock − fold increase RSV) / fold 
increase mock). Means and SD are shown ( n = 3 (A) or 4 (B)). 
Fig. 4. Knock-down of protein phosphatases does not reverse RSV repression of 
dexamethasone-induced GILZ. A549 cells were transfected with siRNA against PP5, 
PP1 and PP2A or a control siRNA. 48 h later they were RSV (MOI = 3)- (black) or 
mock-infected (white) and treated with vehicle or 100 nM dexamethasone for 5 h. 
Dexamethasone-induced GILZ mRNA was determined by real-time PCR and normal- 
ized to GAPDH and CAP-1 (A). % repression by RSV was calculated as previously (B). 






Fig. 5. GR phosphorylation point mutations do not reverse RSV repression of 
dexamethasone-induced MMTVLuc activity. Cos7 cells were transfected with full 
length pCMV HA-hGR, pCMV HA-hGR S203A, pCMV HA-hGR S211A, pCMV HA-hGR 
S226A or pCMV HA-hGR S211A S226A; MMTVLuc promoter; and a control renilla vec- 
tor. They were RSV (MOI = 3)- (black) or mock-infected (white) and treated with 100 
nM dexamethasone for 24 h. Fireﬂy luciferase was normalized to renilla and fold in- 
crease following dexamethasone treatment calculated. Means and SD are shown ( n = 
4). n response to RSV infection ( Fig. 2 ), we generated the double mu- 
ation S211A S226A. All these constructs induced MMTVLuc activity 
n a ligand dependent manner, which was signiﬁcantly repressed by 
SV infection ( Fig. 5 ). 4. Discussion 
We have previously shown that RSV infection of lung epithelial 
cells interferes with glucocorticoid-induced gene activation through 
inhibition of GR-DNA binding [ 11 ]. To further investigate the mech- 
anism by which this repression occurs we sought to identify which 
region of GR was necessary for the repression of GR-mediated trans- 
activation by RSV. Here we have shown that the N-terminal region of 
GR is required for RSV repression of GR-mediated transactivation ( Fig. 
1 ). This region contains AF1, a transactivation domain, and a number 
of GR phosphorylation sites. 
Following ligand treatment, human GR is phosphorylated at ser- 
ine 211, 226 and 203 [ 13 ]. Phosphorylation of serine 211 results in 
GR nuclear localization, DNA binding, and correlates with transcrip- 
tional activity. Phosphorylation of serine 226 also results in nuclear 
localization and DNA binding, whereas phosphorylation of serine 203 
inhibits nuclear localization [ 12 , 13 ]. Given the association of phos- 
phorylation of serine 211 and 226 with transcriptional activity, we 
tested the effect of RSV infection on the ligand-dependent phospho- 
rylation of these sites. RSV infection of A549 cells inhibited ligand 
dependent phosphorylation of both serine 211 and 226 ( Fig. 2 ). 
Changes in phosphorylation state may be the result of changes 
in kinase or phosphatase activity. Treatment with the protein phos- 
phatase inhibitor calyculin A increased GR phosphorylation in the 
absence of RSV-infection suggesting inhibition of endogenous pro- 
tein phosphatase activity that limits ligand-dependent GR phospho- 
rylation. In addition, calyculin A also reversed the effects of RSV on 
ligand dependent phosphorylation ( Fig. 2 ), such that GR phosphory- 
lation levels were similar in mock- and RSV-infected cells, suggesting 
a role for enhanced protein phosphatase activity in the RSV effects on 
GR. Protein phosphatases have previously been implicated in GR func- 
tion. Okadaic acid, a protein phosphatase inhibitor, increases GR-DNA 
binding and nuclear accumulation [ 20 ]. In addition, PP5 is associated 
with the C-terminal LBD of GR [ 21 ] and dephosphorylates GR at ser- 
ine 211 [ 22 ]. Suppression of PP5 increases GR nuclear accumulation, 
DNA binding, and transcriptional activity [ 22 –24 ]. In addition, PP5 has 
been shown to play a role in cytokine suppression of GR transactiva- 
tion [ 25 ]. Although much research has focused on PP5, other protein 
phosphatases may also play a role in regulation of GR phosphoryla- 
tion. For example, PP2A has been reported to play a role in gluco- 
corticoid insensitivity in asthma [ 26 ]. In order to determine if these 
















































































 changes in GR phosphorylation are required for the RSV repression
of GR transactivation, we tested if the protein phosphatase inhibitors
okadaic acid or calyculin A could reverse the effects of RSV infection
on dexamethasone induction of GILZ. We found only a slight, non-
signiﬁcant, reduction in RSV repression of dexamethasone-induced
GILZ mRNA ( Fig. 3 ). In addition, we knocked-down the expression of
PP5, PP1 and PP2A and similarly found only a slight, non-signiﬁcant,
reduction in RSV repression of dexamethasone-induced GILZ mRNA
( Fig. 4 ). It should be noted that we only used individual siRNAs and
there may be some redundancy in these protein phosphatases or with
other protein phosphatases. However, from this data we cannot con-
clude that the RSV changes in GR phosphorylation play a role in RSV
repression of GR transactivation. 
Finally, we tested the effect of RSV on GR phospho point mutations.
Due to the repression of both serine 211 and 226 phosphorylation by
RSV and the fact that some interplay between these phosphorylation
sites has been reported [ 19 , 27 ], we also included the double mu-
tant S211A S226A. RSV infection repressed dexamethasone-induced
transactivation through all of the phospho point mutated GRs as well
as wild-type GR ( Fig. 5 ). These data suggest that RSV mediated changes
in GR phosphorylation alone cannot account for RSV repression of GR
transactivation and that other regions of the N-terminus of GR must
be required. Further studies are needed to investigate which other re-
gions of the N-terminus are required and if these other regions work
in collaboration with these changes in phosphorylation. 
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